Yuan-Di C Halvorsen (Yuan-Di Halvorsen)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 7

Top Topics

Tyrosine Kinase

Drug Administration

Cardiovascular Events

Top Venues

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

John Joseph Valentine McMurray, Scott D Solomon, J Paul Lock, Joseph M Massaro, Fang Zhu, Wenjiong Zhou, Hicham Skali, Eldrin F Lewis, Mason W Freeman, Yuan-Di C Halvorsen
Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin. Diabetes, obesity & metabolism 26 (3) (2023)
John Joseph Valentine McMurray, Scott D Solomon, J Paul Lock, Joseph M Massaro, Fang Zhu, Wenjiong Zhou, Hicham Skali, Eldrin F Lewis, Mason W Freeman, Yuan-Di C Halvorsen
Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin. Diabetes, obesity & metabolism 26 (3) (2023)
Yuan-Di C Halvorsen, Annie L Conery, John Paul Lock, Wenjiong Zhou, Mason W Freeman
Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trial. Diabetes, obesity & metabolism (2023)
John Joseph Valentine McMurray, Scott D Solomon, J Paul Lock, Joseph M Massaro, Fang Zhu, Wenjiong Zhou, Hicham Skali, Eldrin F Lewis, Mason W Freeman, Yuan-Di C Halvorsen
Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin. Diabetes, obesity & metabolism (2023)
John Joseph Valentine McMurray, Scott D Solomon, J Paul Lock, Joseph M Massaro, Fang Zhu, Wenjiong Zhou, Hicham Skali, Eldrin F Lewis, Mason W Freeman, Yuan-Di C Halvorsen
Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin. Diabetes, obesity & metabolism (2023)
Yuan-Di C Halvorsen, John Paul Lock, Juan Pablo Frias, Francisco José Tinahones, Dominik Dahl, Annie L Conery, Mason W Freeman
A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes, obesity & metabolism (2022)
Yuan-Di C Halvorsen, Geoffrey A Walford, Joseph Massaro, Robert P Aftring, Mason W Freeman
A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes. Diabetes, obesity & metabolism 21 (11) (2019)